-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Buy on Axsome Therapeutics, Raises Price Target to $285

Benzinga·09/23/2026 15:50:03
Diffusion vocale
Truist Securities analyst Srikripa Devarakonda maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and raises the price target from $200 to $285.